Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
September 2018
-
Press Release
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects… -
Press Release
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no… -
Press Release
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has… -
Press Release
Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz
Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg… -
Press Release
Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis
Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon… -
Story People and Culture
Nudging bias out of the organization
Our Global Head of Talent Acquisition & Staffing talks about ongoing recruitment efforts to create a more diverse and inclusive organization.
-
Key Release
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
August 2018
-
Story Patient Perspectives
The ABCDEs of melanoma prevention and detection
Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.
-
Press Release
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma… -
Key Release
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising… -
Story Discovery
Teaming up with academia to discover medicines
The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.
-
Press Release
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…